First LSCD patient in UK receives Chiesi’s Holoclar

Pharmaceutical Technology | November 04, 2019

The first patient, funded by the UK’s National Health Service (NHS), has received treatment with Chiesi’s stem-cell-based therapy Holoclar for limbal stem cell deficiency (LSCD) caused by chemical eye burns. The patient received treatment at Newcastle upon Tyne Hospitals NHS Foundation Trust. LSCD is a rare eye disorder, which could result in chronic pain, photophobia, burning, inflammation, stromal scarring, corneal neovascularisation and even blindness. Chiesi’s Holoclar is a form of advanced therapy called a tissue-engineered product, made of cells obtained from the patient’s healthy limbus during a biopsy. The extracted cells are sent to the manufacturing facility at Holostem Terapie Avanzate in Italy to be prepared and grown in a culture to generate a layer of healthy tissue. After a minimum of 50 days, the healthy tissue layer is transported back to the treating hospital for implantation into the damaged eye to repair the damaged corneal surface. The National Institute for Health and Care Excellence (NICE) in the UK recommended the drug in 2017 for the treatment of adults with moderate-to-severe LSCD after eye burns.

Spotlight

In this study, the Toxtyper is used for drug screening in drug consumption rooms which are seen as an important element to minimize drug-related health problems (e.g. infection risk) and promote contact of drug users with employees of drug help programs.

Spotlight

In this study, the Toxtyper is used for drug screening in drug consumption rooms which are seen as an important element to minimize drug-related health problems (e.g. infection risk) and promote contact of drug users with employees of drug help programs.

Related News

PHARMA TECH

Overland Pharmaceuticals Partners with ArisGlobal to Accelerate Safety Capabilities

ArisGlobal | December 08, 2021

ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphere® announced its partnership with Overland Pharmaceuticals. Overland, a premier biopharmaceutical company bringing innovative medicines to underserved patients in Asia and worldwide, selected ArisGlobal's LifeSphere Multivigilance program to centralize pharmacovigilance activities and further develop and commercialize advances in medicine. "Pharmacovigilance is evolving, with greater demands to save time and cost, maintain compliance with shifting global regulations, and effectively aggregate large amounts of data, among other vital tasks, which is why we're excited that Overland has adopted ArisGlobal's LifeSphere Safety platform to manage those challenges. With LifeSphere Multivigilance, Overland will realize efficiency gains and obtain real-time insights into risk-benefit profiles across the product life cycle." Beena Wood, Vice President of Safety at ArisGlobal LifeSphere Multivigilance is an end-to-end, automated system that helps pharmacovigilance teams save time and effort, ensure future-proof compliance, and keep global teams collaboratively aligned. The LifeSphere product suite is used by over 60% of the top 50 biopharma companies worldwide. "Through formative partnerships, such as working with ArisGlobal, Overland will move forward with our mission to develop and commercialize the most promising advances in medicine across carefully selected therapeutic areas," said Roger Luo, Ph.D, Chief Development Officer of Overland. "Our goals are to build innovation for patients, achieve flexibility with business partners, and develop program efficiency by centralizing key operations. We feel that by bringing pharmacovigilance centrally with LifeSphere, we are one step closer to accomplishing that vision." "Safely and rapidly accelerating the development of new medicines is at the core of what we do," adds Rong Zhu, M.D, Ph.D., Head of Drug Safety & Pharmacovigilance at Overland. "Now, by utilizing LifeSphere Multivigilance, we will be able to centralize and scale our pharmacovigilance efforts, strengthen our data fabric, and further utilize effective R&D technology to assist in the development of patient-centric, life-changing therapies." Another key area that sparked alignment across ArisGlobal and Overland includes shared values of global collaboration, agility, and integrity. ArisGlobal's 30+ year tenure in the R&D technology industry will support Overland to architect differing partnership models and bring innovative drugs to underserved patients in Asia and around the world. This news comes on the heels of ArisGlobal's recent Breakthrough Conference, acknowledgment for requirement readiness in Gens & Associates' August 2021 "IDMP Software Vendor Readiness and Capability" report, and accolades by Frost & Sullivan for Customer Value Leadership for 2021. About ArisGlobal ArisGlobal is transforming the way today's most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture. About Overland Pharmaceuticals Overland Pharmaceuticals is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world. By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas. Through formative partnerships, Overland will move forward the development and commercialization of the most promising advances in medicine.

Read More

RESEARCH

Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico

Pluristem | December 30, 2020

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a main regenerative medication organization building up a foundation of novel natural helpful items, reported today it has gone into a coordinated effort concurrence with Mexican drug organization Innovare R&D to extend its continuous clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) related with COVID-19 in Mexico. The Phase II investigation in Mexico is dependent upon the endorsement of neighborhood specialists, with the objective of being led under the U.S. Food and Drug Administration (FDA) cleared convention. As per the arrangement, Innovare will open clinical destinations and enlist patients for the proposed clinical investigation in Mexico. Innovare will subsidize the examination in Mexico and will buy PLX cells for the investigation from Pluristem. Subject to potential positive clinical investigation results and Mexican administrative endorsement for commercialization, the arrangement awards Innovare restrictive conveyance rights in Mexico to supply PLX cells for treating serious COVID-19 cases confounded by ARDS. All protected innovation and assembling rights stay with Pluristem. With 1,389,430 cases and 122,855 passings as of December 29, 2020, Mexico's COVID-19 disease and death rates have been expanding. Mexico has the most elevated passings relatively to COVID-19 cases or populace on the planet as of December 28, 2020, as announced by Johns Hopkins University of Medicine. "We are satisfied to unite with Innovare, a main imaginative organization intending to be important for the answer for battling the COVID-19 pandemic in Mexico," expressed Pluristem CEO and President, Yaky Yanay. "On account of our key upper hand of having in-house producing office, progressed strategic capacities, and a worldwide reach, we can supply PLX cells to clinical bases on the world while broadening our worldwide help for COVID-19 into Latin America. By directing the examination in both the U.S. furthermore, Mexico, in corresponding to the E.U. furthermore, Israel, we are proceeding with our attention on accomplishing clinical achievements and targets, while bringing the expected treatment of PLX cells to those out of luck." Gerardo Cárdenas Vogel, CEO of Innovare R&D remarked, "As an organization that is looking for overall accomplices indicating clinical guarantee for neglected clinical necessities, we are eager to team up with Pluristem. We anticipate utilizing our clinical and business capacities with Pluristem's high level cell treatment answer for help create and possibly bring a genuinely necessary treatment for ARDS patients related with COVID-19 to Mexico."

Read More

BUSINESS INSIGHTS

COEUS Holdings Announces Partnership With Insight Consulting Group (ICG) to Address the Healthcare Industry’s Changing Research and Insight Landscape

COEUS Holdings | September 18, 2021

COEUS Holdings, LLC, and its subsidiaries, together a leading boutique life sciences technology and consulting firm, today announced that it has entered a partnership with Insight Consulting Group (ICG). The partnership seeks to bridge the gaps between payers, healthcare providers, and consumers by developing insights and strategies that are reflective of today’s integrated needs. The partnership will produce and apply comprehensive insights to inform strategy that could advance access to more medications and help to address the unmet needs of Physicians and Patients. While ICG’s expertise, proprietary processes, and deliverables will be leveraged by various organizations that are part of COEUS Holdings’ group of subsidiaries, Mirador Global, led Chuck Peipher, Managing Partner, will be most regularly engaged. Mirador delivers consulting expertise in early commercial development for global and domestic drug commercialization and market access efforts. This partnership takes direct aim at the delivery of game-changing insights and market research that will take shape in a variety of touchpoints through the commercial development process. Together, we’ll be able to work more quickly and effectively through this partnership given the common knowledge of the social sciences, brand development processes, and a commitment to our clients who are focused on serving the needs of Physicians and Patients. - Chris Schnaars, Principal at Insight Consulting Group. Ultimately, all stakeholders in the healthcare ecosystem (patients, caregivers, HCPs, influencers, extenders, payers, and provider organizations) must work together to create an optimal care environment. Through shared resources that deliver deeper research and insights, the ICG and COEUS partnership will facilitate a more comprehensive and robust understanding of how healthcare clients can meet the needs and achieve ideal outcomes for all stakeholders. The ICG and COEUS partnership will enable clients to realize the benefits of working with one team, with end-to-end research and payer capabilities. It’s the combination of insights being leveraged simultaneously during the design and development of marketing and payer strategies that will deliver incremental value to the industry. About ICG ICG inspires deeper healthcare understanding by bringing its clients’ most important interactions into research. Understanding human needs and translating them into behavioral insights is at the forefront of the design of our deliverables. ICG brings high proficiency and experience to analysis of insights, raising the bar of confident decision making and commercial impact. ICG is focused on meeting people where they are (not where we want them to be) and understanding what true core human and emotional needs can be addressed to influence behavior and impact outcomes. About Mirador Global LP Founded in 2016, Mirador Global LP is an international consulting practice that specializes in strategic global commercial development for specialty diseases, including rare diseases, oncology/​immuno-oncology, immunology, and CNS disorders. Mirador Global client engagements are developed bringing together Global Marketing, Analytics, Market Access, HEOR, Medical Affairs, R&D, and other functions delivered by a team of pharmaceutical industry experts. The company provides its clients with a bio-pharma line of sight unlike any other unique to Mirador Global. About COEUS Holdings The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets.

Read More